Sentences with phrase «treatment of a good novel»

While tech / design elements are pro, none help «Septembers of Shiraz» become any less hectic or superficial a treatment of a good novel that should have made for a much more flavorful, thoughtful and moving film.

Not exact matches

«The development of novel treatments demands both a good knowledge of articular cartilage biology and tissue engineering methods.

Children with tuberculosis meningitis — a brain and spinal cord infection that leads to disability and death — have a biological fingerprint that can be used to assess the severity of the condition, help decide the best course of treatment, and provide clues for novel treatments, scientists at the Francis Crick Institute, Imperial College London and the University of Cape Town reveal.

Meanwhile, his research teams are moving several other novel therapies toward clinical trials, each of which has potential for use in the synergistic model of cancer treatment that Black believes will offer the best hope for his patients.

A better understanding of the function of neuromodulators, such as COX - 2 and TIA - 1, may help identify novel therapeutic targets for the treatment of epilepsy.»

«As we assess novel new treatments and techniques evolve, professional associations will continue to champion quality improvement for all providers in the best interest of patients,» said Dr. Fullerton.

This will enable a better understanding of the disease itself, but also of the concrete needs of patients, leading to novel or improved diagnostics and treatments.

Understanding the molecular details of how ICOS exercises its critical influence may allow scientists to manipulate antibody specificity to design better vaccines and create novel treatments for autoimmune disorders.

By identifying novel biological pathways and publishing details of these interactions, the study team aims to help uncover useful targets in developing better vaccines and cancer treatments.

«A drug that blocks heparanase may represent a novel treatment for long - term inflammation associated with HSV - 1 infection as well as other inflammatory disorders of the eye,» he said.

Overall, this work illustrates that better understanding the basic biology of the immune system in preclinical models may open up a window for the development of novel treatments for human autoimmune disease.

The development of novel treatments needs both a good knowledge of articular cartilage biology and tissue engineering methods.

«Our collaboration with VentiRx is part of a broader programmatic effort to partner with top biotech and pharmaceutical companies to develop novel combinations of treatments that may work better together than each would alone,» said Adam Kolom, managing director of CRI's venture fund.

«As we understand the nature of the interaction between viruses and host immunity, we will be better placed to intervene in this delicately balanced arms race in order to develop novel treatments and interventions,» Katzourakis noted.

In line with the objectives of the International Rare Disease Research Consortium (IRDiRC), we aim to develop novel tools that will allow to make more accurate diagnoses, predict the disease course and the efficacy of available treatments, and help developing new and better therapies for rare kidney diseases.

This finding reveals unexpected roles for the microbiome and innate immune signalling in the pathogenesis of a cerebrovascular disease, as well as suggesting novel strategies for its treatment.

Furthermore, the success of this project can lead to the development of novel axon - regenerating therapeutics that could transform the clinical treatment of angle - closure glaucoma and other types of optic neuropathies, as well as have the potential to be adapted to regenerating the long - distance axonal projections damaged by spinal cord injury, brain trauma, and white matter stroke.

The students have undergone a comprehensive education in life science emphasising cutting - edge methods in bioinformatic analysis of big data, high throughput techniques of molecular biology as well as how to translate biological findings into diagnostic tools and novel treatments.

In particular, I have initiated a team approach that is identifying and studying recurrent, treatment - refractory cancers in our clinics using these approaches as a component of evidence - based diagnostic medicine, seeking to better understand the genomic drivers in these cancers and to identify novel treatment approaches that target them, in hopes of obtaining durable responses.

«We are excited to be a part of this important new initiative to develop novel treatment options for patients,» said Ovid Trifan, M.D., Ph.D., chief medical officer of Apexigen, Inc. «APX005M is a potential best - in - class CD40 agonist that works by activating the immune system's antigen - presenting cells in the tumor microenvironment.

Led by Christiana Davis, MD, (in collaboration with Dr. Peter Gabriel, Chief Oncology Informatics Officer and Abigail Doucette, MPH, Research Registry Program Manager), the Thoracic TCE has established project - based databases to track the demographics and response status of patients to immune - oncology treatments, as well as acquired resistance to standard therapies and novel targeted immunotherapies.

Patients will be able to receive the Hutch's novel immunotherapies for cancer at roughly double the capacity that existed before the 9,222 - square - foot clinic opened, and intensive monitoring will enable researchers to better understand why some patients respond, where others do not, and to achieve the goal of developing the best curative approach to treatment for each individual patient.

The goal of our research is to provide doctors with key, additional information to choose best treatment strategies for breast cancers with novel mutations of unknown significance.

Moreover, many patients expressing high levels of HER2 progress or relapse despite receiving the best HER2 - directed treatments, and thus require novel treatment approaches.

The approach is to use clinically relevant tumor models such as patient - derived xenografts (PDXs), as well as humanized and immunocompetent transgenic tumor - bearing mice to design rational combinations of novel and emerging cancer therapies, including tumor - targeting and immune - stimulating therapies, to ultimately improve treatment outcomes for cancer patients.

Features, such as fast parasite killing, good safety margin, a potentially novel mode of action and a distinct chemotype support the clinical development of SC83288, as an intravenous application for the treatment of severe malaria.

My interests lie in leveraging the information hidden in large - scale omics data for better understanding of the mutational processes causing human cancer, for identifying potential cancer prevention strategies, and for developing novel approaches for targeted cancer treatment.

«Having one that seems to mimic the disorder so well, especially in terms of the time course of treatments that work in humans, is potentially very useful for researching novel therapeutics.»

This session will focus on skeletal dysplasias as a model for rare genetic diseases, highlighting tools for collecting natural history data and healthcare needs data; key diagnostic clinical and molecular features; and management, including novel emerging disease - modifying treatments based on better understanding of molecular pathogenesis.

It's a clinical treatment of its subject matter that plays out in a wholly external world with an impossibly introspective delivery that might work well in the inverted storytelling of a novel, but in a movie where things should be shown rather than said, the quotable - but - less - than - notable The Counselor would rather say everything it has to say in words, while showing us as little as possible.

Unusual Typography and Images Jonathan Safran Foer is well known as a literary boy wonder, and his novel Extremely Loud and Incredibly Close features an assortment of pictures and typography treatments that complement the story adeptly.

It discovers and develops novel, small - molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.

Rigel Pharmaceuticals, Inc is a clinical - stage drug development company that discovers and develops novel, small - molecule drugs for the treatment of inflammatory / autoimmune diseases, as well as for certain cancers and metabolic diseases.

The novel treatments are designed for the best outcome possible using the extensive understanding of the biology of cancer.

Pfizer Animal Health and CHF already have a successful history of working together on numerous canine health research initiatives, including the Canine Comparative Oncology & Genomics Consortium housed at the National Cancer Institute, as well as Pfizer Animal Health's novel treatment for canine mast cell tumors.

Her research interests during her residency included novel therapies for the treatment of canine pulmonary hypertension (endothelin) antagonists as well as echocardiographic evaluation of the heart's «pump» function in the setting of mitral valve disease.

Given the limited improvement typically obtained in treatment studies that use peer report measures as outcomes with ADHD samples and the well - documented predictive validity of peer reports for later adjustment, the need for more intensive interventions and novel approaches to address the peer problems of children with ADHD is emphasized.